Pack de 10 viales5 en stockAhorra 17%Retatrutide 60 mg
Péptido de investigación triagonista de GLP-1 / GIP / glucagón
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Solo para uso en investigación. Este compuesto se vende estrictamente para investigación in vitro y fines de laboratorio, y no está destinado al consumo humano ni a uso terapéutico. Al comprar, usted confirma que es un investigador calificado y acepta nuestro aviso legal completo.
Solo quedan 5 packs
Péptido de investigación agonista de triple receptor, estudiado por sus efectos combinados sobre las vías de señalización de GLP-1, GIP y glucagón en aplicaciones de investigación metabólica.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mecanismo
Estudiado por el agonismo simultáneo de los receptores de GLP-1, GIP y glucagón. Investigación asociada con marcadores de tasa metabólica, saciedad y gasto energético en poblaciones de estudio.
Verificado por HPLC frente a una especificación de pureza ≥99 %. Analizado de forma independiente por laboratorios acreditados de terceros.
Retatrutide — preguntas frecuentes
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guías relacionadas con Retatrutide
Los investigadores también exploran
Pack de 10 vialesAhorra 22%MOTS-c
Polvo liofilizado10 mg · 2 strengths
Péptido metabólico de origen mitocondrial
En 2 combinaciones
Pack de 10 vialesAhorra 17%5-Amino-1MQ
Polvo liofilizado50 mg · 3 strengths
Compuesto de investigación inhibidor de NNMT
Pack de 10 vialesAhorra 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Transportador mitocondrial de ácidos grasos
En 1 combinación